TELO shares rose 8% after early lab results showed its experimental drug Telomir-1 killed aggressive HL60 leukemia cells, producing a clear dose-dependent drop in viability. The findings build on prior results in breast, pancreatic and prostate cancer models. Telomir noted leukemia high reliance on iron, which Telomir-1 has previously been shown to reduce within cancer cells.